Objective To investigate the clinical characteristics and pharmaceutical care strategy of immune-related myocarditis induced by PD-1 inhibitor.Methods The diagnosis and treatment process of PD-1 inhibitor-induced immune-related myocarditis treated in Beijing Friendship Hospital Affiliated to Capital Medical University from 2020 to 2023 were retrospectively analyzed,and the clinical characteristics,treatment,and outcome of the patients were analyzed.Results A total of five patients were included,among which two cases were treated with tislelizumab,one case with sintilimab,one case with camrelizumab,and one case with toripalimab.The time from the first treatment with PD-1 inhibitor to a diagnosis of immune-related myocarditis was(36.80±12.74)days.All five cases showed a significant increase in myocardial enzyme spectrum and were treated with glucocorticoids.After treatment,the symptoms of one case were completely improved,and four cases died.Conclusion Immune myocarditis is a rare but severe adverse reaction to PD-1 inhibitors,with a high mortality rate.Physicians and pharmacists should enhance monitoring to detect immune-related myocarditis early.Appropriate dosage,duration of treatment,and patient education during corticosteroid therapy should be provided to enhance medication safety for patients.
关键词
程序性死亡受体1抑制剂/免疫检查点抑制剂/免疫相关性心肌炎/药学监护
Key words
programmed death receptor 1 inhibitor/immune checkpoint inhibitors/immune-related myocarditis/pharmaceutical care
维普
万方数据